Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Locoregional Chemoimmunotherapy and Autologous alpha-DC1 Vaccines in Advanced Ovarian Cancer
NCT02432378Phase 2Withdrawn
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Sep 2015
- Primary completion
- Jun 2025
- Modality
- Whole Cell Cancer Vaccines, Small Interfering RNA (siRNA), Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of αDC1 and rintatolimod in ovarian cancer (2 arms), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Change in the number of CD8+ tumor infiltrating T cells in the peritoneal fluid at 8 weeks and Number of adverse events for the different combinations at 8 weeks. Planned start Sep 2015; status: withdrawn.
02
Drugs
αDC1rintatolimod
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT02432378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02432378.